Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
6.68
+0.64 (10.60%)
At close: Aug 13, 2025, 4:00 PM
6.41
-0.27 (-4.04%)
Pre-market: Aug 14, 2025, 8:57 AM EDT
Solid Biosciences Employees
Solid Biosciences had 100 employees as of December 31, 2024. The number of employees increased by 12 or 13.64% compared to the previous year.
Employees
100
Change (1Y)
12
Growth (1Y)
13.64%
Revenue / Employee
n/a
Profits / Employee
-$1,540,840
Market Cap
520.17M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SLDB News
- 1 day ago - Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 13 days ago - Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 22 days ago - Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) - GlobeNewsWire
- 4 weeks ago - Solid Biosciences: SGT-003's Safety Profile Illuminates DMD Gene Therapy Path (Rating Upgrade) - Seeking Alpha
- 5 weeks ago - SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm - PRNewsWire
- 5 weeks ago - Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) - GlobeNewsWire
- 2 months ago - Solid Biosciences to Participate at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire